HPS2-THRIVE randomized 25, 673 high-risk patients who could tolerate niacin to either placebo or extended-release niacin plus laropiprant (Tredaptive, Merck), an anti-flushing agent, in addition to background therapy.

FORBES: HPS2-THRIVE: A 'Disappointing But Clear' Result